

Differential T cell reactivity to endemic coronaviruses and SARS-CoV-2 in community and health care workers

Ricardo da Silva Antunes^{1,#}, Suresh Pallikkuth^{2,#}, Erin Williams^{3,#}, Esther Dawen Yu¹, Jose Mateus¹, Lorenzo Quiambao¹, Eric Wang¹, Stephen A. Rawlings⁴, Daniel Stadlbauer⁵, Kaijun Jiang⁵, Fatima Amanat^{5,6}, David Arnold³, David Andrews⁷, Irma Fuego³, Jennifer M. Dan^{1,8}, Alba Grifoni¹, Daniela Weiskopf¹, Florian Krammer⁵, Shane Crotty^{1,8}, Michael E. Hoffer^{3,9, ‡}, Savita G. Pahwa^{2, ‡} and Alessandro Sette^{1,8, ‡,*}

¹ Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.

² Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.

³ Department of Otolaryngology, University of Miami, Miller School of Medicine, Miami, FL, 33136, USA.

⁴ Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.

⁵ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

⁶ Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA

⁷ Department of Pathology, University of Miami, Miller School of Medicine, Miami, FL, 33136, USA.

⁸ Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA.

⁹ Department of Neurological Surgery, University of Miami, Miller School of Medicine, Miami, FL, 33136, USA.

These authors contributed equally.

‡ These authors contributed equally.

* Corresponding author: Alessandro Sette (alex@lji.org); 858-405-5638

Summary: CD4⁺ T cell responses against common cold coronaviruses (CCC) are elevated in SARS-CoV-2 seronegative high-risk healthcare workers (HCW) compared to COVID-19 convalescent HCW, suggesting that exposure to SARS-CoV-2 might interfere with CCC responses and/or cross-reactivity a protective effect.

Accepted Manuscript

Abstract

Herein we measured CD4⁺ T cell responses against common cold corona (CCC) viruses and SARS-CoV-2 in high-risk health care workers (HCW) and community controls. We observed higher levels of CCC reactive T cells in SARS-CoV-2 seronegative HCW compared to community donors, consistent with potential higher occupational exposure of HCW to CCC. We further show that SARS-CoV-2 T cell reactivity of seronegative HCW was higher than community controls and correlation between CCC and SARS-CoV-2 responses is consistent with cross-reactivity and not associated with recent in vivo activation. Surprisingly, CCC T cell reactivity was decreased in SARS-CoV-2 infected HCW, suggesting that exposure to SARS-CoV-2 might interfere with CCC responses, either directly or indirectly. This result was unexpected, but consistently detected in independent cohorts derived from Miami and San Diego.

Key words: Coronaviruses, SARS-CoV-2, health care workers, COVID-19, T cells

Accepted Manuscript

Introduction

Healthcare workers (HCW) that provide frontline care during the global pandemic of Coronavirus Disease (COVID-19) are at increased risk of infection due to frequent close and prolonged exposure to patients with SARS-CoV-2 [1]. SARS-CoV-2 infection rates among HCW are still largely undetermined and highly variable depending on the geographical and temporal distribution among other factors [2-5] but higher prevalence has been documented during periods of upsurge [6, 7]. Still, only a minority have developed mild to severe disease manifestations and the majority have remained seronegative for SARS-CoV-2 antibodies despite having close contact with SARS-CoV-2 infected patients [2-4, 8, 9].

Robust T cell immunity has been consistently reported in multiple studies in asymptomatic, acute, and convalescent COVID-19 individuals [8, 10-13]. Furthermore, we and others have previously reported significant pre-existing immune memory responses to SARS-CoV-2 sequences in unexposed subjects [10, 12-15]. Here, we aimed to characterize preexisting SARS-CoV-2 T cell responses in this HCW cohort.

Due to close contact with patients, HCW are particularly prone to exposure to respiratory pathogens such as human coronaviruses (HCoVs) and particularly to endemic “common cold” coronavirus (CCC) [16-18] (<https://www.cdc.gov/niosh/topics/healthcare/infectious.html>). Human CCC are seasonal endemic circulating viruses that cause only mild upper and lower respiratory infections. They are globally distributed with higher incidences in winter months. Little is known about their pattern of infection, transmission rates, or duration of immunity [19-21], however detailed analysis of CCC reactivity from healthy donors and COVID-19 patients have been reported in recent studies [22-24]. As expected, on the basis of their common phylogeny, CCC share varying degrees of sequence homology with SARS-CoV-2 and we and others have shown that cross-reactive CD4⁺ T cell memory responses against SARS-CoV-2 can be detected in unexposed donors [14, 22, 24-26], although pre-existing reactivity cannot solely be explained by prior exposure to CCC [27].

However, it is still unclear how pre-existing immunity impacts disease severity or clinical outcome after SARS-CoV-2 exposure [28, 29] and if this could translate into a protective effect. While some studies suggest this could be the case [23, 30-32], and exposure to CCC concomitantly results in a faster response of pre-existing memory cells to control SARS-CoV-2 infection, it cannot be excluded that CCC cross-reactivity could contribute to drive COVID-19 immunopathogenesis [33]. Thus, it is important to study differences in CCC reactivity and pre-existing immunity in different cohorts, particularly HCW.

Material and Methods

Peripheral blood mononuclear cells (PBMC) and serum isolation and handling

For the Miami cohorts, peripheral venous blood was collected in EDTA vacutainer tubes and PBMC were isolated by density gradient isolation using Ficoll-Paque (Lymphoprep, Nycomed Pharma, Oslo, Norway) as previously described [34] and stored in liquid nitrogen until use. Serum was collected and stored at -80°C. For the San Diego cohorts, whole blood was collected in heparin coated blood bags (healthy unexposed donors) or in ACD tubes (COVID-19 donors) and PBMCs isolated as above. All samples were obtained after written informed consent from the participants in an anonymous fashion and with protocols approved by the respective institutional review boards (IRB).

OC43, NL63, HKU1, 229E and SARS-CoV-2 Enzyme-linked immunosorbent assay (ELISA)

The CCC (OC43 spike, 229E spike, NL63 spike or HKU1 spike) ELISAs were performed as previously described [35] and the endpoint titers determined. The SARS-CoV-2 ELISAs for all cohorts with the exception of SIP were performed as previously described in detail [35] following a two-step ELISA protocol and results interpreted in accordance with the manufacturer's cutoff calculations. Limits of detection were set at 1:80 and 1:50 for CCC and SARS-CoV-2 ELISA's respectively. All data below was plotted as 1:25. For the SIP cohort, a

N-antigen ELISA assay for IgG and IgM that was purely qualitative was performed. All donors had undetectable levels of antibodies.

Epitope predictions and peptide selection

To investigate CCC CD4⁺ T cell responses, we performed prediction of peptides for HLA class II spanning the entire sequence of the 4 CCC strains utilizing the Immune Epitope Database and Analysis Resource (IEDB) [36]. After selection of promiscuous binders, epitopes composed of 15-mer were generated and further divided into 2 different peptide pools (MP) to encompass epitopes sharing 60% or less homology with SARS-CoV-2 sequences or more than 67% homology (**Supplementary Table 1**). Responses were measured against the two different MPs separately, and summed together for graphic display. The CMV MP is a pool of previously reported Class I and Class II epitopes [37]. To study T cell responses against SARS-CoV-2, we used the entire SARS-CoV-2 genome (GenBank: MN908947) and we generated MPs of 15-mer peptides overlapping by 10 spanning the entire protein sequence (6-253 peptides per pool) or alternatively a MP for the remainder genome consistent of dominant HLA Class II predicted CD4⁺ T cell epitopes as previously described [36, 38]. **Supplementary Table 1** lists the number of peptides pooled for each of the viral proteins. Alternatively, HLA Class I predicted CD8⁺ T cell epitopes prediction was performed as previously reported, using NetMHC pan EL 4.0 algorithm [39] (**Supplementary Table 1**). All peptides were synthesized as crude material (A&A, San Diego, CA).

Activation induced markers (AIM) assay and memory phenotype

Cryopreserved cells were thawed, washed and stimulated for flow cytometry determinations using activation induced cell marker (AIM) assays as previously described [34, 40]. Antibodies used in the AIM assay as well as the gating strategy used to define AIM reactive cells and memory sub-populations is listed in **Supplementary Table 2** and

Supplementary Figure 1. All samples were acquired on a ZE5 Cell analyzer (Bio-rad laboratories), and analyzed with FlowJo software (Tree Star, San Carlos, CA).

Statistical analysis

Data and statistical analyses were done in FlowJo 10 and GraphPad Prism 8.4, unless otherwise stated. Non-parametric Mann-Whitney or Kruskal-Wallis test were applied for unpaired two-group or three-group comparisons, respectively. Correlation analysis were performed using non-parametric Spearman test. Details pertaining to significance are also noted in the respective legends and $p < 0.05$ defined as statistical significant. Additional data analysis details are described in the respective figure legends.

Results

Characteristics of the donor cohorts investigated

Five different cohorts of subjects were enrolled in the study (**Table 1**). Three cohorts were recruited in the Miami metropolitan area and two cohorts were recruited in the San Diego metropolitan area. Two cohorts from Miami encompassed high-risk HCW, further classified as seroNegative Healthcare Workers (NHCW) or Antibody or PCR Positive Healthcare Workers (PHCW). Effort was placed by the study team to balance these cohorts in gender, age, and medical specialty. A third Miami cohort designated Shelter In Place (SIP) of community volunteers who were all seronegative and with no exposure to known infected persons was included as a control group. The two additional cohorts were asymptomatic unexposed and seroNegative donors from San Diego (NSD), and COVID-19 seropositive subjects also from the San Diego region (COVID-19SD). (see **Supplementary data**, for more details on the selection process of all the cohorts). All subjects were assigned to positive or negative SARS-CoV-2 categories on the basis of PCR and/or serological tests.

Serological analysis of the different donor cohorts

Serum samples for all five donor cohorts were tested for SARS-CoV-2 using the enzyme linked immunosorbent assay (ELISA) (see methods for detail). The results are shown in **Figure 1A**. Significant SARS-CoV-2 titers were detected in almost all cases of individuals in the HCW cohort with COVID-19 disease from Miami (23/26). Conversely, the seronegative cohorts from Miami (NHCW) had undetectable titers or below the limit of detection. Likewise, all COVID-19SD had significant SARS-CoV-2 titers, while none of the NSD donors was seropositive for SARS-CoV-2 spike antibodies.

In parallel, seropositivity for the spike proteins of the four endemic common cold coronaviruses (CCC; 229E, NL63, HKU1 and OC43), was also determined in the three donor cohorts from Miami (**Figure 1B**). All donors had detectable titers and variable reactivity for each of the CCC strains and consistent with the majority of the general population having detectable responses for the CCC viruses [19, 20]. In conclusion, these data define the serological status of the donor cohorts for which the T cell reactivity was investigated.

CD4⁺ T cell reactivity against CCC is higher in NHCW compared to SIP and PHCW

To test the various Miami cohorts for CD4⁺ T cell reactivity, we performed Activation Induced Marker (AIM) assays [34, 40], previously utilized to characterize viral responses including SARS-CoV-2 CD4⁺ T cell responses [12, 13, 15], using sets of predicted dominant Class II-restricted T cell peptides, for each of the four CCCs (**Supplementary Table 1**). This epitope prediction strategy was previously applied in multiple studies [34, 36, 40] and was envisioned to capture the top 50% of the predicted response.

The CD4⁺ T cell reactivity to the 229E, NL63, HKU1 and OC43 viruses was higher in the NHCW cohort, as compared to the SIP cohort (**Figures 2a-b** show absolute magnitude

and stimulation index (SI) plots). This difference was most pronounced for NL63 and least pronounced for HKU1 (p values ranged from 0.03 to 0.0005 by the Kruskal-Wallis test).

By contrast, NHCW CD4⁺ T cell reactivity was significantly higher compared to PHCW against 229E, NL63 and OC43 (p values ranging from 0.004 to 0.002). For HKU1 there was a trend toward higher responses (p=0.12). No difference was noted with a control MP composed of epitopes derived from the unrelated ubiquitous cytomegalovirus (CMV) pathogen [37]. Representative flow cytometry plots with CCC-specific and CMV CD4⁺ T cell responses are shown in **Figure 2c**. The SARS-CoV-2 infected donors analyzed were associated with either mild or asymptomatic disease (**Table 1**). We have analyzed responses to CCC in the cohort of PHCW segregating asymptomatic individuals (n=7) vs. individuals with mild disease (n=19) and no differences were observed (data not shown).

CD4⁺ T cell reactivity against CCC is higher in unexposed compared to COVID-19 donors in an independent cohort

To validate these results further, we assessed CCC responses in two additional cohorts recruited in the San Diego region, selected on the basis of being asymptomatic and seronegative (NSD) or symptomatic and seropositive (COVID-19SD) for SARS-CoV-2 infection. (**Table 1**). Both cohorts were recruited between March and July of 2020, similar to the Miami cohort.

The 229E, NL63, HKU1 and OC43 epitope pools displayed higher CD4⁺ T cell reactivity in the unexposed donors, as compared to the COVID-19 diagnosed donors (**Figures 3a-b**). No differences between groups were observed in the responses against the CMV control MP. These results indicate that healthy unexposed donors demonstrate higher CD4⁺ T cell reactivity against CCC than COVID-19 donors.

CD4⁺ T cell reactivity to SARS-CoV-2 S and CD4R MPs

Next, we tested the various cohorts from the Miami area for SARS-CoV-2 CD4⁺ T cell reactivity, using the AIM assay as before and previously described MPs, one encompassing overlapping peptides spanning the entire sequence of the SARS-CoV-2 spike protein (S), and one encompassing predicted CD4⁺ T cell epitopes from the remainder of the genome (CD4R) [12, 36] (**Supplementary Table 1**). The results are shown in **Figure 4**, which depict CD4⁺ T cell responses in the various cohorts plotted as background subtracted data or as stimulation index. A representative flow cytometry AIM⁺ gating is shown in **Supplementary Figure 2**.

CD4⁺ T cell responses from PHCW cohort were highest, in accordance with their recent exposure to SARS-CoV-2, followed by responses measured in the NHCW and then the SIP cohort. More specifically, the total CD4⁺ T cell reactivity of the PHCW cohort to the SARS-CoV-2 pools was significantly higher than both NHCW ($p = 0.03$ and $p = 0.003$ by the Kruskal-Wallis test for absolute and SI readouts, respectively) and SIP ($p = 0.002$ and $p < 0.0001$ by the Kruskal-Wallis test for absolute and SI readouts, respectively). Of further interest, the total CD4⁺ T cell reactivity of NHCW was also higher than that observed in the SIP cohort ($p = 0.04$ for both absolute and SI readouts). No difference was noted in the case of the CMV MP. As shown in **Supplementary Figure 3**, the differences noted above, are further confirmed by assessing the total reactivity obtained by summing the responses to the various individual SARS-CoV-2 antigen pools as previously reported [12]. Analysis of the expression of the CCR7 and CD45RA memory markers confirmed that the CD4⁺ T cell reactivity in all three cohorts was mediated by memory T cell subsets (**Supplementary Figure 4**).

SARS-CoV-2 reactivity in NHCW is not likely due to resolved SARS-CoV-2 infections in absence of seroconversion

We also analyzed the AIM⁺ CD4⁺ T cells for expression of the HLA-DR/CD38 markers, which have been found increased in donors from mild to acute SARS-CoV-2 infection, and therefore to be associated with recent *in vivo* activation [11, 41]. The data shown in **Figure 5**, demonstrates that the CD4⁺ T cell reactivity to SARS-CoV-2 peptides is associated with an increased fraction of recently activated T cells in the case of the PHCW cohort, as compared to the NHCW or SIP cohorts. No difference was detected in the case of the epitope pool derived from the control ubiquitous antigen CMV. In conclusion, the analysis of HLA DR/CD38 markers results are most consistent with recent SARS-CoV-2 infection of the PHCW cohort but not of the NHCW or SIP cohorts.

Having measured CCC specific responses we further examined responses on a donor-by-donor basis, and asked whether donors with high CCC CD4⁺ T cell reactivity also have high SARS-CoV-2 CD4⁺ T cell reactivity. A strong correlation was detected between total CD4⁺ T cell responses to CCC and SARS-CoV-2 (**Supplementary Figure 5**) in all the cohorts and for all CCC strains (significant p values ranged from 0.015 to <0.0001 and correlation rank from 0.47 to 0.78), while no correlation was observed between SARS-CoV-2 and CMV responses.

CD8⁺ T cell reactivity to SARS-CoV-2 epitopes

Finally, we measured CD8⁺ T cell reactivity to SARS-CoV-2 epitopes (**Supplementary Table 1**) in the various cohorts as previously described [12, 13], utilizing a pool of overlapping peptides spanning the S antigen, and two MPs containing SARS-CoV-2 predicted HLA binders for the 12 most common HLA A and B alleles (CD8A and CD8B MPs) (**Supplementary Table 1**). **Figure 6** shows CD8⁺ T cell responses plotted as background subtracted data, or plotted as stimulation index, against the S pool, the two different CD8A

and CD8B epitope summed together, and the control CMV pool. A representative flow cytometry AIM⁺ gating is shown in **Supplementary Figure 6**.

In the case of the S pool, the CD8⁺ T cell response to SARS-CoV-2 spike protein was highest in PHCW (and similar between SIP and NHCW). More specifically, the total CD8⁺ T cell reactivity of the PHCW cohort to the SARS-CoV-2 pools was significantly higher than both NHCW ($p=0.001$ and $p<0.0001$ by the Kruskal-Wallis test for both absolute and SI readouts) and SIP ($p=0.0003$ and $p=0.0003$ for both absolute and SI readouts), as expected on the basis of the SARS-CoV-2 infection. The reactivity of the SIP and NHCW was not significantly different.

Similarly, with the CD8A+B pools, the total CD8⁺ T cell reactivity of the PHCW cohort to the SARS-CoV-2 pools was higher than both NHCW ($p=0.004$ and $p=0.0003$ for both absolute and SI readouts) and SIP ($p <0.0001$ and 0.0003 for both absolute and SI readouts). CD8⁺ T cell reactivity in all three cohorts was mediated by memory T cell subsets and associated with recently activated HLA-DR⁺CD38⁺ cells in the PHCW cohort (**Supplementary Figure 7**). Overall these data suggest that the higher reactivity observed in NHCW as compared to SIP is largely confined to CD4⁺ T cell responses and only marginally seen in the case of CD8⁺ T cell responses, further suggesting that it is not resulting from infected individuals rapidly becoming seronegative.

Discussion

Here we present evidence for differential reactivity to endemic CCC and SARS-CoV-2 epitopes. Although previous reports studied responses to CCC or SARS-CoV-2 in either unexposed or COVID-19 survivors [22-24], this is the first study, to the best of our knowledge, investigating T cell and antibody responses measured simultaneously for both CCC and SARS-CoV-2 and in particular by presenting evidence for differentially T cell reactivity among high-risk HCW and community workers. In particular, we show that a cohort of HCW with presumed exposure to respiratory viruses is associated with higher levels of

CCC reactive T cells as compared to a community SIP cohort, with presumed lower CCC exposure. Interestingly, similar CCC antibody levels were observed across all cohorts.

We hypothesized that this elevated level of CD4⁺ T cell reactivity was associated with higher reactivity against SARS-CoV-2 sequences, and indeed we show significantly higher levels of reactivity to SARS-CoV-2 sequences in the NHCW cohort. There is a correlation between CD4⁺ T cell responses to SARS-CoV-2 and CCC. While this correlation is not unexpected in SARS-CoV-2 negative individuals [15, 26, 28], it was not expected in the COVID-19 survivors. It is possible that this finding is reflective of the fact that while most of the response in the COVID-19 survivors, in whom much of the T cell response is expected to be SARS-CoV-2-specific, also the CCC-cross-reactive component is expanded, thus maintaining a positive correlation. Further studies are required to clarify the evolution of repertoires in exposed and unexposed individuals.

We also analyzed SARS-CoV-2 CD8⁺ T cell responses and observed a trend towards higher levels of SARS-CoV-2 cross-reactive CD8⁺ T cells in the NHCW compared to SIP controls. Both COVID-19 survivors and uninfected controls have SARS-CoV-2 specific T cell responses that are statistically different but not distinguishable on an individual basis (i.e., there is extensive overlap between populations). While it is possible that some of the NHCW may have been infected in absence of seroconversion, or have been associated with transient seroconversion, we believe this is unlikely/infrequent. Furthermore, our analysis found expression of cell markers associated with recent in vivo activation [11, 41] exclusively elevated in PHCW for both CD4⁺ and CD8⁺ T cell responses against SARS-CoV-2. As such, the patterns of reactivity detected in the NHCW are likely representative of a sampling of uninfected Miami HCW.

Samples from SARS-CoV-2 infected subjects were associated with lower levels of CCC reactivity as compared to non-exposed donors. This result was unexpected, but consistently detected in independent cohorts derived from Miami and San Diego. Several

possibilities exist regarding the potential mechanisms underlying this effect. It is possible that SARS-CoV-2 infection may result in a generalized inhibition of CD4⁺ T cell responses to other CCCs but not unrelated viruses such as CMV. Impaired responses particularly associated with type I interferon activity in COVID-19 patients were also described in a recent report [42], suggesting that SARS-CoV-2 might interfere with innate immunity. SARS-CoV-2 infection may also result in expansion of SARS-CoV-2-specific, non-CCC reactive T cells, competing with the pre-existing CCC specificities [22, 43]. Pre-existing CCC reactivity and different pre-exposure history can also influence disease severity and infection [28]. Indeed, the repertoire of cross-reactive T cells in HCW might have a protective effect against SARS-CoV-2 infection as suggested in other studies [23, 30, 31]. Based on our current understanding of viral dynamics, it appears unlikely that CD4⁺ T cells might be able to prevent disease, but it is possible that their presence may lead to rapid termination of infection and only transient seropositivity ([26, 44] and see above). It is also possible that CD8⁺ T cells might mediate or contribute to rapid termination of infection as described for SARS-CoV [45, 46] and other viral infection diseases [47, 48].

Limitations of the present study

All recruited SARS-CoV-2 infected donors were associated with mild or asymptomatic disease, and the small sample size of the study does not allow to address whether levels of preexisting cross-reactive CCC T cell responses might influence disease severity [28, 30]. Also, it would be expected that HCW would wear PPE during the pandemic period, so it seems unlikely that they would be exposed to CCC to a great extent, at least in the workplace. It is therefore possible that, despite our effort to balance HCW and SIP control cohort, other demographic differences could explain the results. Larger sample sizes will be required to analyze this issue in this type of cross-sectional design, but it is likely that a prospective longitudinal design might be necessary to firmly address this point based on

evaluation of CCC reactivity in pre-infection samples, and its correlation with disease severity post SARS-CoV-2 infection. Also, increased cell numbers would allow to perform a more granular analysis of the CCC-specific responses and address if T cell response to CCC in HCW is multi-specific or if it becomes more focused to only few epitopes after SARS-CoV-2 infection. Functional characterization or assessment of T cell phenotypes was also not performed. It would certainly be of interest to elucidate cytokine responses or other functional assays in ensuing studies involving HCW. This study has focused on dissecting the CCC CD4⁺T cells responses by design, as scarce ex-vivo cross-reactivity has been previously observed for the CD8⁺ T cell counterpart [12]. Nevertheless, we cannot exclude an involvement of CD8⁺ T cells and future studies should be focused to specifically address this point. An additional limitation of this study is the unknown history of previous CCC exposure. Therefore, the results may not be necessarily generalizable to other situations with different patterns of prior exposure.

Accepted Manuscript

Footnotes

Conflict of interest

A.S. is a consultant for Gritstone, Flow Pharma, Merck, Epiogenesis, Gilead and Avalia. S.C. is a consultant for Avalia. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. Mount Sinai has licensed serological assays to commercial entities and has filed for patent protection for serological assays. D.S., F.A., and F.K. are listed as inventors on the pending patent application (F.K.), and Newcastle disease virus (NDV)-based SARS-CoV-2 vaccines that name F.K. as inventor. Mount Sinai has licensed serological assays to commercial entities and has filed for patent protection for serological assays. D.S., F.A. and F.K. are listed as inventors on the pending patent application. All other authors declare no conflict of interest

Funding

This work was supported by the National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID) under awards AI142742 (Cooperative Centers for Human Immunology) (A.S., S.C.), NIH contract Nr. 75N9301900065 (D.W., A.S.), U01 AI141995-03 (A.S.), and U01 CA260541-01 (D.W). This work was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C (FK, for reagent generation), Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 (FK, for reagent generation), NIH NIA R01 AG068110-01A1 (S.G.P, S.P), Miami CTSI emerging disease proposal (D.J., S.G.P, S.P.), University of Miami Institutional Support and the generous support of the JPB foundation, the Open Philanthropy Project (#2020-215611) and other philanthropic donations.

Corresponding author contact information

Alessandro Sette (alex@lji.org), 858-349-2720; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.

The research in this manuscript has not been presented at any meetings.

No author has changed affiliation since completion of this study

Author contributions

Conceptualization: S.G.P., M.E.H. and A.S. Formal analysis: R.dSA, E.D.Y, S.P. and E.W. Funding acquisition: S.G.P. F.K. M.E.H and A.S. Investigation: R.dSA., S.P., E.W., E.D.Y., J.M., L.Q., D.S., K.J., F.A., and I.F. Resources: F.K., E.W., S.A.R., J.M.D, D.Ar., and D.An. Supervision: D.W., S.C, R.dSA., M.E.H., S.G.P, and A.S.; Writing: R.dSA, E.W., F.K., M.E.H., S.G.P. and A.S. R.dSA., S.P. and E.W. are equally first contributing authors for their shared efforts in the experimental work and investigation including clinical cohort coordination besides other described roles. S.G.P., M.E.H. and A.S are equally last contributing authors for their shared efforts in the supervision of the work besides the abovementioned roles. No gender or age bias were taken in consideration in the decision of the authors list order.

Acknowledgments

We would like to thank Kizzmekia Corbett and Barney Graham at the Vaccine Research Center at NIH for providing plasmids for CCC spike expression. We wish to acknowledge all subjects for their participation and for donating their blood and time for this study. We thank the Clinical Core of the La Jolla Institute for Immunology and UCSD for sample collection and Allan Watson from Biorad for technical support with ZE5 Cell analyzer.

References

1. Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. *Lancet Public Health* **2020**; 5:e475-e83.
2. Iversen K, Bundgaard H, Hasselbalch RB, et al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. *Lancet Infect Dis* **2020**.
3. Moscola J, Sembajwe G, Jarrett M, et al. Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area. *JAMA* **2020**; 324:893-5.
4. Rudberg AS, Havervall S, Manberg A, et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. *Nat Commun* **2020**; 11:5064.
5. Zhang S, Guo M, Wu F, et al. Factors associated with asymptomatic infection in health-care workers with severe acute respiratory syndrome coronavirus 2 infection in Wuhan, China: a multicentre retrospective cohort study. *Clin Microbiol Infect* **2020**.
6. Venugopal U, Jilani N, Rabah S, et al. SARS-CoV-2 Seroprevalence Among Health Care Workers in a New York City Hospital: A Cross-Sectional Analysis During the COVID-19 Pandemic. *Int J Infect Dis* **2020**.
7. Reynolds CJ, Swadling L, Gibbons JM, et al. Healthcare workers with mild / asymptomatic SARS-CoV-2 infection show T cell responses and neutralising antibodies after the first wave. Preprint at doi.org/10.1101/2020.10.13.20211763 **2020**.
8. Vallejo A, Vizcarra P, Quereda C, Moreno A, Casado JL. SARS-CoV-2 cellular immune responses in uninfected health care workers. Preprint at <https://1021203/rs3rs-55720/v1> **2020**.
9. Sotgiu G, Barassi A, Miozzo M, et al. SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital. *BMC Pulm Med* **2020**; 20:203.
10. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature* **2020**; 584:457-62.
11. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell* **2020**; 183:158-68 e14.
12. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* **2020**; 181:1489-501 e15.
13. Rydzynski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell* **2020**.
14. Braun J, Loyal L, Frentsch M, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. *Nature* **2020**.
15. Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science* **2020**.
16. English KM, Langley JM, McGeer A, et al. Contact among healthcare workers in the hospital setting: developing the evidence base for innovative approaches to infection control. *BMC Infect Dis* **2018**; 18:184.
17. Chughtai AA, Stelzer-Braid S, Rawlinson W, et al. Contamination by respiratory viruses on outer surface of medical masks used by hospital healthcare workers. *BMC Infect Dis* **2019**; 19:491.
18. Jacobs JL, Ohde S, Takahashi O, Tokuda Y, Omata F, Fukui T. Use of surgical face masks to reduce the incidence of the common cold among health care workers in Japan: a randomized controlled trial. *Am J Infect Control* **2009**; 37:417-9.
19. Killerby ME, Biggs HM, Haynes A, et al. Human coronavirus circulation in the United States 2014-2017. *J Clin Virol* **2018**; 101:52-6.
20. Nickbakhsh S, Ho A, Marques DFP, McMenamin J, Gunson RN, Murcia PR. Epidemiology of Seasonal Coronaviruses: Establishing the Context for the Emergence of Coronavirus Disease 2019. *J Infect Dis* **2020**; 222:17-25.
21. Cimolai N. Complicating Infections Associated with Common Endemic Human Respiratory Coronaviruses. *Health Secur* **2020**.
22. Bacher P, Rosati E, Esser D, et al. Low-Avidity CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. *Immunity* **2020**; 53:1258-71 e5.
23. Bonifacius A, Tischer-Zimmermann S, Dragon AC, et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. *Immunity* **2021**.
24. Woldemeskel BA, Kwaa AK, Garliss CC, Laeyendecker O, Ray SC, Blankson JN. Healthy donor T-cell responses to common cold coronaviruses and SARS-CoV-2. *J Clin Invest* **2020**.
25. Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science* **2020**; 370:89-94.

26. Nelde A, Bilich T, Heitmann JS, et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. *Nat Immunol* **2020**.
27. Reche PA. Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines. *Front Immunol* **2020**; 11:586984.
28. Lipsitch M, Grad YH, Sette A, Crotty S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. *Nat Rev Immunol* **2020**.
29. Meyerholz DK, Perlman S. Does common cold coronavirus infection protect against severe SARS-CoV2 disease? *J Clin Invest* **2020**.
30. Sagar M, Reifler K, Rossi M, et al. Recent endemic coronavirus infection is associated with less severe COVID-19. *J Clin Invest* **2020**.
31. Wyllie D, Mulchandani R, Hayley E Jones, et al. SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: A prospective cohort study in keyworkers. Preprint at <https://doi.org/10.1101/2020110220222778>; **2020**.
32. Henss L, Scholz T, von Rhein C, et al. Analysis of humoral immune responses in SARS-CoV-2 infected patients. *J Infect Dis* **2020**.
33. Beretta A, Cranage M, Zipeto D. Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis? *Front Immunol* **2020**; 11:567710.
34. da Silva Antunes R, Babor M, Carpenter C, et al. Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters. *J Clin Invest* **2018**; 128:3853-65.
35. Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. *Curr Protoc Microbiol* **2020**; 57:e100.
36. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. *Cell Host Microbe* **2020**; 27:671-80 e2.
37. Carrasco Pro S, Sidney J, Paul S, et al. Automatic Generation of Validated Specific Epitope Sets. *Journal of immunology research* **2015**; 2015:763461.
38. Grifoni A, Voic H, Dhanda SK, et al. T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species. *J Virol* **2020**; 94.
39. Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data. *Journal of immunology* **2017**; 199:3360-8.
40. da Silva Antunes R, Paul S, Sidney J, et al. Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses. *PloS one* **2017**; 12:e0169086.
41. Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. *Sci Immunol* **2020**; 5.
42. Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* **2020**; 369:718-24.
43. Tarke A, Sidney J, Kidd CK, et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Preprint at <https://doi.org/10.1101/20201208416750> **2020**.
44. Elong Ngono A, Young MP, Bunz M, et al. CD4+ T cells promote humoral immunity and viral control during Zika virus infection. *PLoS Pathog* **2019**; 15:e1007474.
45. Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. *J Virol* **2014**; 88:11034-44.
46. Chen H, Hou J, Jiang X, et al. Response of memory CD8+ T cells to severe acute respiratory syndrome (SARS) coronavirus in recovered SARS patients and healthy individuals. *Journal of immunology* **2005**; 175:591-8.
47. Hemann EA, Kang SM, Legge KL. Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination. *Journal of immunology* **2013**; 191:2486-94.
48. Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. *J Virol* **2003**; 77:68-76.

Figure Legends

Figure 1. SARS-CoV-2 and CCC viruses serological reactivity for the donor cohort. (A) Serum ELISA titers to SARS-CoV-2 spike RBD protein. “ND” = Not Determined. (B) Serum ELISA titers to CCC viruses (HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43) spike protein. Non-parametric Kruskal-Wallis multiple comparison test was applied for each individual CCC strain. Geometric mean titers are indicated and p values are shown for the statistical significant comparisons. “SIP” = Shelter In Place community volunteers (n=33). “NHCW” = SeroNegative Health Care Workers (n=31). “PHCW” = Antibody or PCR Positive Health Care Workers (n=26). “NSD” = SeroNegative San Diego (n=15). “COVID-19” = Seropositive San Diego (n=10). Dotted line indicates limit of detection (1:50).

Figure 2. CD4+ T cell immune responses to CCC epitopes from Miami are higher in NHCW.

CCC-specific CD4⁺ T cells (HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43) and ubiquitous control CMV-specific CD4⁺ T cells were measured as percentage of AIM⁺ (OX40⁺CD137⁺) CD4⁺ T cells after stimulation of PBMCs with CCC and CMV peptide pools. (A) Data background subtracted or (B) stimulation index (SI) against DMSO negative control are shown with geometric mean for the 3 different groups. Non-parametric Kruskal-Wallis multiple comparison test was applied for each individual CCC strain and CMV. P values are shown for the statistical significant comparisons. “SIP” = Shelter In Place community volunteers (n=33). “NHCW” = SeroNegative Health Care Workers (n=31). “PHCW” = Antibody or PCR Positive Health Care Workers (n=26). (C) Representative FACS plots, gated on total CD4⁺ T cells for the 4 CCC in addition to the DMSO and CMV across all the cohorts. Cell frequency for AIM⁺ cells in the several conditions is indicated.

Figure 3. Reactivity of CD4⁺ T cells against CCC epitopes in an independent cohort from San Diego.

CCC-specific CD4⁺ T cells (HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43) and ubiquitous control CMV-specific CD4⁺ T cells were measured as percentage of AIM⁺ (OX40⁺CD137⁺) CD4⁺ T cells after stimulation of PBMCs with CCC and CMV peptide pools. (A) Data background subtracted or (B) stimulation index (SI) against DMSO negative control are shown with geometric mean for the 2 different groups. Samples were from unexposed seronegative donors (“NSD”, n=15) and recovered COVID-19 patients (“COVID-19”, n=10). Statistical comparisons across cohorts were performed with the Mann-Whitney test. P values are shown with p<0.05 defined as statistical significant.

Figure 4. CD4⁺ T cell response to SARS-CoV-2 epitopes highest in PHCW and lowest in SIP.

SARS-CoV-2-specific CD4⁺ T cells were measured as percentage of AIM⁺ (OX40⁺CD137⁺) CD4⁺ T cells after stimulation of PBMCs with peptide pools encompassing spike (“S”) or representing all the proteome without spike (“CD4R”). Graphs show data for specific responses against S, CD4R or the combination of both (CD4-total) and against CMV as a control, and plotted as (A) background subtracted or (B) as stimulation index (SI) against DMSO negative control. Geometric mean for the 3 different groups is shown. Non-parametric Kruskal-Wallis multiple comparison test was applied. P values are shown for the statistical significant comparisons. “SIP” = Shelter In Place community volunteers (n=33). “NHCW” = SeroNegative Health Care Workers (n=31). “PHCW” = Antibody or PCR Positive Health Care Workers (n=26).

Figure 5. Highest PHCW reactivity in CD4⁺ T cell responses associated with recent infection.

(A) Recently activated SARS-CoV-2-specific CD4⁺ T cells were measured as percentage of CD38⁺/HLA-DR⁺ cells in AIM⁺ (OX40⁺CD137⁺) CD4⁺ T cells after stimulation of PBMCs with peptide pools encompassing a spike only (“S”) MP and MP representing all the proteome without spike (“CD4R”). Graphs show data for specific responses against SARS-CoV-2 (both “S” and “CD4R”) the ubiquitous pathogen CMV of responses with SI>2. Each dot represents the response of an individual subject to an individual pool. Geometric mean for the 3 different groups is shown. Non-parametric

Kruskal-Wallis multiple comparison test was applied. P values are shown for the statistical significant comparisons. "SIP" = Shelter In Place community volunteers (n=20). "NHCW" = SeroNegative Health Care Workers (n=33). "PHCW" = Antibody or PCR Positive Health Care Workers (n=39). (B) Representative FACS plots of HLA-DR/CD38⁺ cells in AIM⁺ (OX40⁺CD137⁺) CD4⁺ T cells (colored) overlapped with total HLA-DR⁺/CD38⁺ expression (grey) for all the cohorts in the different unstimulated or stimulated conditions. Cell frequency of HLA-DR⁺/CD38⁺ in AIM⁺ cells or total CD4⁺ T cells is indicated on the top and bottom right corner respectively.

Figure 6. CD8⁺ T cell response to SARS-CoV-2 epitopes highest in PHCW and lowest in SIP.

SARS-CoV-2-specific CD8⁺ T cells were measured as percentage of AIM⁺ (CD69⁺CD137⁺) CD8⁺ T cells after stimulation of PBMCs with spike only ("S") MP or class I MPs (CD8A, CD8B). Graphs show data for specific responses against S, the combination of both CD8 MPs (CD8-total) and against CMV as a control, and plotted as (A) background subtracted or (B) as stimulation index (SI) against DMSO negative control. Geometric mean for the 3 different groups is shown. Non-parametric Kruskal-Wallis multiple comparison test was applied. P values are shown for the statistical significant comparisons. "SIP" = Shelter In Place community volunteers (n=33). "NHCW" = SeroNegative Health Care Workers (n=31). "PHCW" = Antibody or PCR Positive Health Care Workers (n=26).

Tables

Table 1. Description of donor cohort characteristics and demographics

Cohort Name	NHCW ⁺	PHCW ⁺⁺	SIP ⁺⁺⁺	NSD ⁺⁺⁺⁺	COVID-19 SD ⁺⁺⁺⁺⁺
Geographical Location	Miami	Miami	Miami	San Diego	San Diego
Number of donors	32	26	33	15	10
Gender (M/F)	(17, 15)	(13, 13)	(16, 17)	(7, 8)	(3, 7)
Mean age (years)	41	38	41	41	32
Sample collection date	Apr-Jun 2020	Aug 2020	Jun 2020	Mar-Jun 2020	Apr-Jul 2020
SARS-CoV-2 status	Ab(-)	Ab(+) or PCR(+)	Ab(-)	Ab(-)	Ab(+)
SARS-CoV-2 PCR (n (%))					
Positive	0 (0)	22 (84.6)	0 (0)	0 (0)	7 (70)
Unknown	-	4 (15.4)	-	-	3 (30)
Antibody response (n (%))					
Positive	0 (0)	23 (88.5)	0 (0)	0 (0)	10 (100)
Negative	32 (100)	3 (11.5)	33 (100)	15 (100)	0 (0)
Interval exposure to sample collection (days)					
Range	-	20-145	-	-	43-140
Median	-	44	-	-	92
Symptoms (n (%))					
Asymptomatic	32 (100)	7 (26.9)	33 (100)	15 (100)	0 (0)
Mild	-	19 (73)	-	-	8 (80)
Moderate	-	0 (0)	-	-	1 (10)
Severe	-	0 (0)	-	-	1 (10)
Medical speciality (n (%))					
Otolaryngology	17 (53.1)	6 (23.1)	-	-	-
Anesthesiology	5 (15.6)	3 (11.5)	-	-	-
Emergency Medicine	5 (15.6)	5 (19.2)	-	-	-
Ophthalmology	2 (6.3)	2 (7.7)	-	-	-
Other (internal medicine, surgery, etc.)	3 (9.4)	10 (38.5)	-	-	-

+ indicates seronegative high-risk health care workers from Miami; ++ indicates antibody (Ab) /PCR positive high-risk health care workers from Miami; +++ indicates seronegative community donors with no patient exposure from Miami; ++++ indicates seronegative unexposed donors from San Diego; +++++ indicates seropositive donors from San Diego.

Figure 1




Figure 2





Figure 3



Accer

Figure 4




Figure 5




Figure 6

